Acumen Pharmaceuticals pays off K2 HealthVentures loan, cuts 52 jobs
The company terminated its 2023 term loan with a $23.3 million payoff and moved forward with a workforce reduction tied to halting its sabirnetug program.
SEC filing
4 stories
The company terminated its 2023 term loan with a $23.3 million payoff and moved forward with a workforce reduction tied to halting its sabirnetug program.
SEC filing
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
ALTITUDE-AD missed its primary cognitive endpoint at both doses, and Acumen will stop development of sabirnetug while weighing strategic options.
SEC filing
Acumen Pharmaceuticals said it expects topline results from its Phase 2 sabirnetug trial in November 2026 and reported $78.6 million in cash as of September 30, 2026.
SEC filing